Cargando…

An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma

Background: Tumor mutational burden (TMB) was verified to be closely associated with immune checkpoint inhibitors, but it is unclear whether gene mutation has an effect on immunotherapy of hepatocellular carcinoma (HCC). This research aimed to investigate the underlying correlation between gene muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mo, Zhuomao, Wang, Yongdan, Cao, Zhirui, Li, Pan, Zhang, Shijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304048/ https://www.ncbi.nlm.nih.gov/pubmed/32596147 http://dx.doi.org/10.3389/fonc.2020.00853

Ejemplares similares

An Integrative Analysis Reveals the Potential Mechanism between Herbal Medicine Yinchen and Immunoregulation in Hepatocellular Carcinoma
por: Mo, Zhuomao, et al.
Publicado: (2020)

Novel Molecular Subtypes Associated With 5mC Methylation and Their Role in Hepatocellular Carcinoma Immunotherapy
por: Mo, Zhuomao, et al.
Publicado: (2020)

Exosome CTLA-4 Regulates PTEN/CD44 Signal Pathway in Spleen Deficiency Internal Environment to Promote Invasion and Metastasis of Hepatocellular Carcinoma
por: Wang, Yongdan, et al.
Publicado: (2021)

A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Artemisia annua on the Treatment of Hepatocellular Carcinoma
por: Zhang, Shuqiao, et al.
Publicado: (2021)

A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor
por: Mo, Zhuomao, et al.
Publicado: (2021)

Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation
por: Ding, Xiao, et al.
Publicado: (2014)

Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma
por: Mo, Zhuomao, et al.
Publicado: (2021)

A Novel Signature Based on mTORC1 Pathway in Hepatocellular Carcinoma
por: Mo, Zhuomao, et al.
Publicado: (2020)

Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma
por: Lee, Seung Eun, et al.
Publicado: (2016)

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma
por: Chen, Lin, et al.
Publicado: (2021)

SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway
por: Tang, Xiaohui, et al.
Publicado: (2021)

Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis
por: Travaglino, Antonio, et al.
Publicado: (2022)

Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

Case Report: Targeted Therapy for Metastatic Solid Pseudopapillary Neoplasm of the Pancreas With CTNNB1 and PTEN Mutations
por: Wang, Xinbo, et al.
Publicado: (2021)

Depressive Disorder promotes Hepatocellular Carcinoma metastasis via upregulation of ABCG2 gene expression and maintenance of self-renewal
por: Hu, Hao, et al.
Publicado: (2020)

Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma
por: Zhu, Jun, et al.
Publicado: (2022)

Identification of a Hypoxia-Associated Signature for Lung Adenocarcinoma
por: Mo, Zhuomao, et al.
Publicado: (2020)

Prognostic significance of CTNNB1 mutation in hepatocellular carcinoma: a systematic review and meta-analysis
por: Lu, Genlin, et al.
Publicado: (2023)

A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report
por: Shang, Yu, et al.
Publicado: (2022)

Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
por: Zhong, Cheng, et al.
Publicado: (2021)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

Detection of CTNNB1 Hotspot Mutations in Cell-Free DNA from the Urine of Hepatocellular Carcinoma Patients
por: Lin, Selena Y., et al.
Publicado: (2021)

Multiple Omics Integration Reveals Key Circular RNAs in Hepatocellular Carcinoma
por: Huang, Zi-Li, et al.
Publicado: (2021)

Integrated Multi-Omics Data Analysis Reveals Associations Between Glycosylation and Stemness in Hepatocellular Carcinoma
por: Liu, Peiyan, et al.
Publicado: (2022)

Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand
por: Galy, Olivier, et al.
Publicado: (2011)

Investigation of CTNNB1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection
por: Javanmard, Davod, et al.
Publicado: (2020)

Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma
por: Oversoe, Stine Karlsen, et al.
Publicado: (2021)

Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience
por: Ogawa, Keita, et al.
Publicado: (2022)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

CTNNB1 Mutation in Aldosterone Producing Adenoma
por: Wang, Jian-Jhong, et al.
Publicado: (2017)

CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma
por: Apps, J. R., et al.
Publicado: (2020)

Recurrent CTNNB1 mutations in craniofacial osteomas
por: Baumhoer, Daniel, et al.
Publicado: (2021)

Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma
por: Pezzuto, Francesca, et al.
Publicado: (2016)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in Hepatocellular Carcinoma
por: Hu, Hao, et al.
Publicado: (2020)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m3katr221a583mkkpkfiu08ruq